About The Company
Cortical Dynamics Ltd is an independent Australian Perth based neurotechnology startup developing innovative brain monitoring technologies and AI based Apps that address a global market exceeding 200 million operations per year where general anaesthetics, analgesics and opioids are administered in the operating room.
Our Brain Anaesthesia Response Monitor or BARM ™ was specifically developed with leading anaesthesiologists worldwide to solve problems associated with anaesthetic and analgesic delivery in the operating theatre and the negative associated interoperative and post- operative consequences which are not widely known. We plan to take our products to the ICU and ER in due course.
Our generation 1 tech BARM™ is FDA(510k), CE, TGA and Korean MFDS approved. We are finalising development of our gen 2 BARM™ in preparation for clinical trials, regulatory approvals and commercial rollout in 2026.
Directors
Ashley Zimpel
Business developer, corporate financier and investment banker with broad financial markets experience and a strong focus on innovation and business strategy. 35 year track record of founding, investing in and establishing businesses in financial capital markets, agribusiness and fintech. Held senior level positions at financial institutions and ASX listed companies including Macquarie Bank and Bankers Trust Australia.
David Breeze
Corporate finance specialist with extensive experience in the stock broking industry and capital markets. He also hold the role of Chairman of Grandbridge Ltd and BPH Energy Ltd, both ASX listed businesses.
Charles Chang
Formed Accolade, Inc. in 2000 and then Susterra EnVision in 2017, a developer of renewable energy solutions. Provides strategic advisory services to domestic/foreign corporates and private equity. Develop renewable solutions. Prior to Accolade, Managing Director at Bankers Trust. MSc. from Dartmouth and B.A. in Economics from University of California Berkeley. Served on several boards. US citizen, currently resides in Korea.
BARM™ Can Play a Vital Role in Enhanced Recovery After Surgery (ERAS)
ERAS is a multimodal perioperative care pathway designed to achieve early recovery for patients undergoing major surgery focusing on the sparing use of opioids and analgesics.
Opioid- sparing techniques are key components to ERAS program. Many patients trace their first exposure to opioids to use during interoperative and post operative pain relief. ERAS programs can reduce patients ‘ consumption and reliance on opioids by 60 %.
2019 –Saint Mary’s Hospital, Trinity Health of New England, in Waterbury, Connecticut USA- Case Study
Saint Mary’s Hospital (SMH) implementing an ERAS program improved their outcomes in nearly all surgical specialties, including shortening length of stay (LOS) by 30% to 50%, with similar reductions in complications and decreased readmissions. Compared to standard care, ERAS protocols produced cost savings of up to US$7,129 per patient.
Improved Clinical Outcomes and a US$2.25 Million Financial Impact
In July 2018, SMH analysed the impact of the first three years of their ERAS program with the following findings:
A two-day decrease in the average LOS resulted in increased revenue of US$750,000 (an increased revenue of nearly US$5,000 per patient).
Many patients were discharged after 2.3 days. For each one-day decrease in LOS, SMH revenue per patient rose by US$2,406.
SMH rate of SSIs has dropped from a statistically acceptable rate of 15% in 2014 to less than 2%, resulting in a US$1.5 million savings.
The combined financial impact of ERAS program (cost savings plus increased revenue) was US$2.25 million in its first three years.
The BARM™ system
CD BAR sensors collect and conduct electrical signals (EEG) from a patients’ forehead and mastoid to the BARM™ Data Acquisition Module which processes the EEG and then feeds the data to the display Monitor as waveforms, indexes and graphs where they are interpreted by the anaesthesiologist
BARM™ G2 stand-alone system
